TY - JOUR
T1 - Biolimus-Eluting Stents With Biodegradable Polymer Versus Bare-Metal Stents in Acute Myocardial Infarction
AU - Räber, Lorenz
AU - Kelbaek, Henning
AU - Taniwaki, Masanori
AU - Ostojic, Miodrag C.
AU - Heg, Dik
AU - Baumbach, Andreas
AU - von Birgelen, Clemens
AU - Roffi, Marco
AU - Tüller, David
AU - Engstrøm, Thomas
AU - Moschovitis, Aris
AU - Pedrazzini, Giovanni
AU - Wenaweser, Peter
AU - Kornowski, Ran
AU - Weber, Klaus
AU - Lüscher, Thomas F.
AU - Matter, Christian M.
AU - Meier, Bernard
AU - Jüni, Peter
AU - Windecker, Stephan
PY - 2014/5/20
Y1 - 2014/5/20
N2 - Background - This study sought to determine whether the 1-year differences in major adverse cardiac event between a stent eluting biolimus from a biodegradable polymer and bare-metal stents (BMSs) in the COMFORTABLE trial (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) were sustained during long-term follow-up.Methods and Results - A total of 1061 patients were randomly assigned to biolimus-eluting stent (BES) and BMS at 11 centers, and follow-up rates at 2 years were 96.3%. A subgroup of 103 patients underwent angiography at 13 months. At 2 years, differences in the primary end point of cardiac death, target-vessel myocardial infarction, and target lesion revascularization continued to diverge in favor of BES-treated patients (5.8%) compared with BMS-treated patients (11.9%; hazard ratio=0.48; 95% confidence interval, 0.31–0.72; P<0.001) with a significant risk reduction during the second year of follow-up (hazard ratio 1–2 years=0.45; 95% confidence interval, 0.20–1.00; P=0.049). Differences in the primary end point were driven by a reduction in target lesion revascularization (3.1% versus 8.2%; P<0.001) and target-vessel reinfarction (1.3% versus 3.4%; P=0.023). The composite of death, any reinfarction and revascularization (14.5% versus 19.3%; P=0.03), and cardiac death or target-vessel myocardial infarction (4.2% versus 7.2%; P=0.036) were less frequent among BES-treated patients compared with BMS-treated patients. The 13-month angiographic in-stent percent diameter stenosis amounted to 12.0±7.2 in BES- and 39.6±25.2 in BMS-treated lesions (P<0.001).Conclusions - Among patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention, BES continued to improve cardiovascular events compared with BMS beyond 1 year
AB - Background - This study sought to determine whether the 1-year differences in major adverse cardiac event between a stent eluting biolimus from a biodegradable polymer and bare-metal stents (BMSs) in the COMFORTABLE trial (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) were sustained during long-term follow-up.Methods and Results - A total of 1061 patients were randomly assigned to biolimus-eluting stent (BES) and BMS at 11 centers, and follow-up rates at 2 years were 96.3%. A subgroup of 103 patients underwent angiography at 13 months. At 2 years, differences in the primary end point of cardiac death, target-vessel myocardial infarction, and target lesion revascularization continued to diverge in favor of BES-treated patients (5.8%) compared with BMS-treated patients (11.9%; hazard ratio=0.48; 95% confidence interval, 0.31–0.72; P<0.001) with a significant risk reduction during the second year of follow-up (hazard ratio 1–2 years=0.45; 95% confidence interval, 0.20–1.00; P=0.049). Differences in the primary end point were driven by a reduction in target lesion revascularization (3.1% versus 8.2%; P<0.001) and target-vessel reinfarction (1.3% versus 3.4%; P=0.023). The composite of death, any reinfarction and revascularization (14.5% versus 19.3%; P=0.03), and cardiac death or target-vessel myocardial infarction (4.2% versus 7.2%; P=0.036) were less frequent among BES-treated patients compared with BMS-treated patients. The 13-month angiographic in-stent percent diameter stenosis amounted to 12.0±7.2 in BES- and 39.6±25.2 in BMS-treated lesions (P<0.001).Conclusions - Among patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention, BES continued to improve cardiovascular events compared with BMS beyond 1 year
KW - METIS-307087
KW - IR-93180
U2 - 10.1161/CIRCINTERVENTIONS.113.001440
DO - 10.1161/CIRCINTERVENTIONS.113.001440
M3 - Article
SN - 1941-7640
VL - 7
SP - 355
EP - 364
JO - Circulation : cardiovascular interventions
JF - Circulation : cardiovascular interventions
ER -
